Aurobindo Pharma: (I) Expansion Of The Biologics Manufacturing Facilities And Entering Into CMO Operations; And (Ii) Entering Into CMO Operations In Vaccines Cgmp Manufacturing - Reg. | Value Research

Aurobindo Pharma: (I) Expansion Of The Biologics Manufacturing Facilities And Entering Into CMO Operations; And (Ii) Entering Into CMO Operations In Vaccines Cgmp Manufacturing - Reg.

(i) The Board of Directors of our 100% subsidiary company CuraTeQ Biologics Pvt. Ltd. (CuraTeQ) at its meeting held today September 1 2022 has decided the following; To expand its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements. The capital expenditure for ramping up capacities is estimated to be around Rs.300 crores. Subject to regulatory approvals and other factors the facility is likely to be fully operational by FY 2026. To enter into contract manufacturing operations (CMO) for biologicals for effective utilization of capacities and augmenting the business prospects in this area as the global biologics contract manufacturing demand is growing at 8 to 10% rate. CuraTeQ will actively seek customers in CMO area. (ii) The Board of Directors of our 100% subsidiary company Auro Vaccines Pvt. Ltd..........

Click here to view PDF


Other Categories